Search Results
Abdul Rehman Syed
Abdul Rehman Syed
University of Calgary, Calgary, Alberta, Canada
Search for other papers by Abdul Rehman Syed in
Google Scholar
PubMed
Search for other papers by Abdul Rehman Syed in
Google Scholar
PubMed
Aakash Gorana
Aakash Gorana
Arnie Charbonneau Cancer Institute, Cumming School of Medicine, University of Calgary, Alberta, Canada
Search for other papers by Aakash Gorana in
Google Scholar
PubMed
Search for other papers by Aakash Gorana in
Google Scholar
PubMed
Erik Nohr
Erik Nohr
Alberta Precision Laboratories, Molecular Pathology Program, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
Search for other papers by Erik Nohr in
Google Scholar
PubMed
Search for other papers by Erik Nohr in
Google Scholar
PubMed
Xiaoli-Kat Yuan
Xiaoli-Kat Yuan
Precision Oncology Hub Laboratory, Tom Baker Cancer Centre, Calgary, Alberta, Canada
Search for other papers by Xiaoli-Kat Yuan in
Google Scholar
PubMed
Search for other papers by Xiaoli-Kat Yuan in
Google Scholar
PubMed
Parthiv Amin MASc
Parthiv Amin MASc
Department of Radiology, Cumming School of Medicine, University of Calgary, Calgary Alberta, Canada
Search for other papers by Parthiv Amin MASc in
Google Scholar
PubMed
Search for other papers by Parthiv Amin MASc in
Google Scholar
PubMed
Sana Ghaznavi
Sana Ghaznavi
Arnie Charbonneau Cancer Institute, Department of Medicine, Section of Endocrinology, University of Calgary, Calgary, Alberta, Canada
Search for other papers by Sana Ghaznavi in
Google Scholar
PubMed
Search for other papers by Sana Ghaznavi in
Google Scholar
PubMed
Debbie Lamb
Debbie Lamb
Arnie Charbonneau Cancer Institute, Cumming School of Medicine, University of Calgary, Alberta, Canada
Search for other papers by Debbie Lamb in
Google Scholar
PubMed
Search for other papers by Debbie Lamb in
Google Scholar
PubMed
John McIntyre
John McIntyre
Precision Oncology Hub Laboratory, Tom Baker Cancer Centre, Calgary, Alberta, Canada
Search for other papers by John McIntyre in
Google Scholar
PubMed
Search for other papers by John McIntyre in
Google Scholar
PubMed
Markus Eszlinger
Markus Eszlinger
Department of Oncology, Cumming School of Medicine, and Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta, Canada
Search for other papers by Markus Eszlinger in
Google Scholar
PubMed
Search for other papers by Markus Eszlinger in
Google Scholar
PubMed
Ralf Paschke
Ralf Paschke
Departments of Medicine, Section of Endocrinology, Oncology, Pathology and Laboratory Medicine, Biochemistry and Molecular Biology and Arnie Charbonneau Cancer Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
Search for other papers by Ralf Paschke in
Google Scholar
PubMed
Search for other papers by Ralf Paschke in
Google Scholar
PubMed
significant uptake, confirming restoration of RAI-avidity (post- 131 I treatment WBS, Fig. 3 ). In addition, a chest CT conducted in May 2022 (1 month before larotrectinib treatment) visualized target lesion 1 measured at 8 × 6 mm, while the target lesion 2
Josef Köhrle
Josef Köhrle
Institut für Experimentelle Endokrinologie, Charité Campus Virchow-Klinikum (CVK), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
Search for other papers by Josef Köhrle in
Google Scholar
PubMed
Search for other papers by Josef Köhrle in
Google Scholar
PubMed
chromatographic and immunoassay methods. rT3 concentrations in blood are equimolar or sometimes even higher than those of the active hormone T3 (Table 1 ) and typically changes are inverse to those of T3 [40, 41, 59, 72, 73, 85, 93]. rT3 is an avid substrate for
